Oxymorphone

A review

Eric Prommer

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalSupportive Care in Cancer
Volume14
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Oxymorphone
Opioid Analgesics
Pain
Drug Compounding
United States Food and Drug Administration
Morphine
Pharmacology

Keywords

  • Opioid
  • Opioid receptors
  • Oxymorphone
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Oxymorphone : A review. / Prommer, Eric.

In: Supportive Care in Cancer, Vol. 14, No. 2, 02.2006, p. 109-115.

Research output: Contribution to journalArticle

Prommer, Eric. / Oxymorphone : A review. In: Supportive Care in Cancer. 2006 ; Vol. 14, No. 2. pp. 109-115.
@article{0222d5b47c204127b894cf4c63be6ea7,
title = "Oxymorphone: A review",
abstract = "Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.",
keywords = "Opioid, Opioid receptors, Oxymorphone, Pharmacokinetics",
author = "Eric Prommer",
year = "2006",
month = "2",
doi = "10.1007/s00520-005-0917-1",
language = "English (US)",
volume = "14",
pages = "109--115",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Oxymorphone

T2 - A review

AU - Prommer, Eric

PY - 2006/2

Y1 - 2006/2

N2 - Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

AB - Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

KW - Opioid

KW - Opioid receptors

KW - Oxymorphone

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=31044432216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31044432216&partnerID=8YFLogxK

U2 - 10.1007/s00520-005-0917-1

DO - 10.1007/s00520-005-0917-1

M3 - Article

VL - 14

SP - 109

EP - 115

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -